GEN-MKT-18-7897-A
Dec 6, 2016 | Blogs, Food / Beverage | 0 comments
Are you looking for ways to up the ante on your LC-MS/MS when it comes to food testing? Researchers here have developed a method for the analysis of approximately 400 pesticides in food samples, and their work is available for viewing in this year’s compendium. This application note is just one of 16 you will find under Pesticides >
Using your QTRAP® LC-MS/MS System at its Full Potential OverviewUsing MRM mode, the QTRAP® 6500 LC-MS/MS was used to quantify hundreds of pesticides in food samples with high selectivity and sensitivity. Identification was further confirmed using MRM ratio identification. An alternative approach for compound identification went beyond the detection of multiple fragments.
Details of ExperimentTwenty pesticides were spiked into different food samples, and diluted extracts were analyzed using two methods.
Results and ConclusionsImproved data processing using a dual injection approach with automatic quantitation, identification, and confirmation using MasterView™ and MultiQuant™ Software. Results highlight the complementary nature of MRM ratios and MS/MS full scan offering a possibility of confirmatory analysis.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network